Dimensional Fund Advisors LP Boosts Stock Position in Xencor, Inc. (NASDAQ:XNCR)

Dimensional Fund Advisors LP boosted its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,501,532 shares of the biopharmaceutical company's stock after buying an additional 102,297 shares during the period. Dimensional Fund Advisors LP owned approximately 2.15% of Xencor worth $34,509,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in XNCR. Finepoint Capital LP purchased a new stake in Xencor during the fourth quarter valued at $15,167,000. Vanguard Group Inc. lifted its stake in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock valued at $184,239,000 after purchasing an additional 418,040 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Xencor by 21.3% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,092,346 shares of the biopharmaceutical company's stock worth $25,102,000 after purchasing an additional 192,080 shares during the period. Geode Capital Management LLC raised its holdings in Xencor by 12.3% during the 4th quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after buying an additional 179,526 shares during the period. Finally, Barclays PLC lifted its position in Xencor by 112.6% in the fourth quarter. Barclays PLC now owns 330,745 shares of the biopharmaceutical company's stock worth $7,600,000 after buying an additional 175,177 shares during the last quarter.

Analyst Ratings Changes

A number of research firms recently commented on XNCR. StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research report on Wednesday, April 30th. Barclays lowered their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday. Finally, William Blair started coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating for the company. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.

Insider Buying and Selling at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. This trade represents a 8.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.76% of the stock is owned by insiders.

Xencor Stock Down 5.2 %

Shares of NASDAQ XNCR traded down $0.46 during midday trading on Friday, reaching $8.33. 935,748 shares of the company's stock traded hands, compared to its average volume of 641,132. The company has a market cap of $592.70 million, a price-to-earnings ratio of -2.60 and a beta of 0.99. The stock's 50 day simple moving average is $10.73 and its 200-day simple moving average is $17.63. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company's revenue was up 104.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.11) earnings per share. On average, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.